Japan Radiotherapy Market Analysis

Japan Radiotherapy Market Analysis
A sample report on

This report presents a strategic analysis of the Japan Radiotherapy
Market and a forecast for its development in the medium and long
term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Japan Radiotherapy Market, and offers unmatched
value, accuracy, and expert insights.

3
A Sample Report on Japan Radiotherapy Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (80%), Primary Research (20%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Market Overview 09-17
1.1. Market Overview: Global
1.2. Overview: Japan
1.3. Economic Overview: Japan
1.4. Statistics at a Glance: Japan
1.5. Digital Health in Japan
1.6. Healthcare Scenario in Japan
1.7. Health Insurance Coverage: Japan
2. Market Size and Forecasting 18-23
2.1. Market Size and Forecasts
2.2. Market Segmentation
2.2.1. By Technology

5
Table of Content
CONTENT PG. NO.
2.2.2. By Application
2.2.3. By End User
3. Market Dynamics 24-28
3.1. Market Growth Drivers
3.1.1. Japan Radiotherapy Market Driver 1
3.2. Market Restraints
3.2.1. Japan Radiotherapy Market Restraint 1
4. Competitive Landscape 29-36

6
Table of Content
CONTENT PG. NO.
4.1. Key Company Profile
4.1.1. Hitachi Ltd.
4.1.2. Toshiba Corporation
4.1.3. Mitsubishi Electric Corporation
4.1.4. IHI Corporation
4.1.5. Sumitomo Heavy Industries Ltd.
4.1.6. Shimadzu Corporation
4.1.7. Elekta K.K.
4.1.8. Hamamatsu Photonics K.K.
4.1.9. Osaka Heavy Ion Therapy Center
4.1.10. Varian Medical Systems
5. Regulatory & Reimbursement Scenario 37-40

7
Table of Content
CONTENT PG. NO.
5.1. Regulatory Scenario
5.2. Reimbursement Regulation

Radiotherapy
▪ Radiotherapy, also known as radiation therapy, is a medical treatment that uses high doses of
radiation to target and kill cancer cells. It is a crucial component in the management of various
cancers and is employed with the goal of either curing the cancer, controlling its growth, or
relieving symptoms
▪ Radiotherapy works by damaging the DNA inside the targeted cells, preventing them from dividing
and, ultimately, leading to their destruction
There are two primary types of radiotherapy: external beam and internal (brachytherapy)
▪ External Beam Radiotherapy: This is the more common form of radiotherapy. It involves directing a focused
beam of radiation from outside the body onto the cancerous cells. The patient typically receives treatment on an
outpatient basis, and the sessions are carefully planned to maximize the radiation's impact on the cancer while
minimizing exposure to surrounding healthy tissues
▪ Internal Radiation Therapy: In this type of radiotherapy, radioactive sources are placed directly inside or very
close to the tumor. This allows for a highly targeted dose of radiation to be delivered to the cancer cells while
reducing exposure to nearby normal tissues. This therapy is commonly used in the treatment of prostate,
breast, and gynecological cancers

1. Market Overview

10
1.1 Market Overview: Global Scenario of Radiotherapy
Illustrative
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$6.9 Bn
is the estimated global
market for radiotherapy
for 2022
43.1%
Is the market share ofNorth
America in the world
0.4 Mn
Children develop cancer
each year
<60%
patients have access to
radiotherapy in middle income
countries
10 Mn+
Deaths due to cancer, 1/3rd of
which is due to tobacco
consumption
50%
of all patients with cancer
worldwide require
radiotherapy

11
1.1 Market Overview: Global
North America
~Market Size of
$3.6 Bn
Europe
~Revenue to reach
$3.2 Bn by 2030
APAC
-Fastest CAGR
Africa
~Market Size of
$xx Bn
Illustrative
Japan
~Market Size of
$xx Bn

12
1.2 Overview: Japan
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
125 Mn +
Population of Japan
in 2022
49.1
Is the median age
in Japan, in 2022
4.2 Tn
Is the Gross Domestic
Product (GDP) in
Japan in 2022
11.5%
of Japan’s GDP is spent
on health in 2022

13
1.3 Economic Overview: Japan
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Japan, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Japan, (2020-2030)
Population Split (2023)
Male
49%
Female
51%
By Gender By Age Group
0-14
15-24
25-54
55-64
65+
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

14
1.4 Statistics at a Glance: Japan
Japan Radiotherapy Market Statistics
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Japan
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
283,000
number of patients who
received radiotherapy in
2019
1 Mn+
newly diagnosed patients with
cancer in the country per year
50%-60%
of patients with cancer
needed radiotherapy as part
of their cancer treatment
<30%
of patients with cancer had
access to radiotherapy in Japan

15
1.5 Digital Health in Japan
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan Digital Health Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Digital Health market in Japan, which includes the market size, current trends and
other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

16
1.6 Healthcare Scenario in Japan
Illustrative
Healthcare scenario in Japan is characterized by a robust system that provides universal access to high-quality
healthcare services
▪ National Health Insurance (NHI): Every Japanese citizen and resident
(except short-term residents) can subscribe to NHI
▪ Public health insurance covers most citizens/residents and the system
pays 70% or more of medical and prescription drug costs with the
remainder being covered by the patient
Public Health Insurance
▪ Around X% of the total population in Japan
▪ Pricing is
Private Health Insurance
▪ Japan public healthcare is funded by the
Cost of Healthcare System in Japan

17
1.7 Health Insurance Coverage: Japan
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2022, most people (98.3%) had health insurance coverage at some point during 2022 and 1.7 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Public (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
58,541 60,226 0.5
58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2022)
Number of People By Health Insurance Coverage
Illustrative

2. Market Size and Forecasting

19
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will get an understanding
of the overall market, which includes the
market size, current trends and other details
related to the topic
trends, and other relevant information related
to the topic or subject matter of interest
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan Radiotherapy Market Forecast,
2022-2030 (in $Bn)
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
($Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Japan Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Japan Market Size ($Bn) 61 74 84 87 91 95 99 106
Illustrative
2.1 Market Size and Forecasts

20
▪ In this section you will get an understanding of the segmentations which will cover the Japan Radiotherapy Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Technology
External Beam Radiation Therapy
Internal Beam Radiation Therapy
Others
By Application
Lung Cancer
Prostate
Colon
Breast
Others
By End User
Hospitals
Radiotherapy Centers
Research Institutes
Illustrative
2.2 Snapshot of Radiotherapy Market Segmentation

21
Japan Radiotherapy Market Share,
By Technology (2022)
▪ External Beam Radiation Therapy in
Japan is a significant component of the
overall Market
final report
information related to the topic
Illustrative
2.2.1 Market Segmentation: By Technology
External Beam
Radiation
Therapy
Internal Beam
Radiation
Therapy
Others

22
By Application (2022)
▪ Lung Cancer applications dominate the
market compared to other segments
with a substantial xx%
final report
Illustrative
2.2.2 Market Segmentation: By Application
Lung Cancer
Prostate Cancer
Colon Cancer
Breast
Cancer
Others

23
▪ Hospitals in Japan are a significant
contributor to the overall Market
final report
Illustrative
2.2.3 Market Segmentation: By End User
Hospitals
Radiotherapy
Centers
Research
Institutes
By End User (2022)

3. Market Dynamics

25
3.1 Market Growth Drivers
3.1.1 By 2050, cancer prevalence in Japan is projected to reach 3,665,900 (3,210,200 to 4,201,400) thousand cases,
representing a 13.1% increase from 2020
Prevalence of various Cancers
Lung
Stomach
Prostate
Colon
Breast
Rectum
Liver
Pancreas
Bladder
Non-Hodgkin…
Oesophagus
Kidney
Thyroid
Corpus uteri
Leukaemia
Cervix uteri
Lip, oral cavity
Ovary
Gallbladder
Brain, central…
▪ Shifts in dietary patterns, alterations in cigarette
consumption, changes in the age of marriage, variations in
the number of births, and advancements in cancer
screening, diagnosis, and treatment collectively account for
the observed changes in cancer prevalence
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Illustrative

26
3.1 Market Growth Drivers (continued)
3.1.2 Continuous advancements in radiotherapy technologies, coupled with substantial capital investment
▪ Ranked as the 3rd largest market globally for radiation
oncology, Japan is home to the National Cancer Center
Hospital, a prominent national cancer treatment facility with
a rich history of delivering patient care for over six decades
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Illustrative
Top Technology & Investment
Type Investment
XX 30.1%
YY 23.4%
ZZ 13.5%

27
3.1 Market Growth Drivers (continued)
▪ Organizations such as the National Institutes for Quantum and
Radiological Science and Technology (QST) and the National Institute of
Radiological Sciences (NIRS) have played a pivotal role in advancing
heavy ion radiotherapy using carbon ions.
▪ such collaborative approach not only facilitates crucial clinical trials but
also accelerates the development and adoption of novel radiotherapy
techniques, positioning Japan as a leader in cancer diagnosis and
treatment
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.3 Collaborative efforts between public and private entities, combined with substantial funding for clinical trials
Clinical Trials Participation in Japan
Illustrative

28
3.2.1 Limited Access to Advanced
Radiotherapy Technologies
▪ Access to advanced
radiotherapy technologies may
be constrained by factors such
as high initial costs, limited
infrastructure, and regional
disparities in healthcare
resources
▪ This limitation can impede the
widespread adoption of cutting-
edge radiotherapy modalities,
restricting patient access to the
latest and most effective
treatments
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
3.2.2 Workforce Shortages and
Training Gaps
▪ A shortage of skilled
professionals in the field of
radiotherapy, including
oncologists and radiography
professionals, poses a significant
restraint. The demand for
radiotherapy services may
outpace the availability of trained
personnel, leading to challenges
in delivering timely and quality
treatments
3.2.3 Regulatory Challenges and
Compliance Burdens
▪ Stringent regulations may pose
challenges for market players in
terms of product approvals,
certifications, and adherence to
evolving standards, potentially
slowing down the introduction of
new technologies and treatments
▪ Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
information related to the topic or
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
3.2 Market Restraints

4. Competitive Landscape

30
Key Note:
Hitachi Ltd.
1
Shimadzu
Corporation
6
Toshiba Corporation
2 Elekta K.K.
7
Mitsubishi Electric
Corporation
3
Hamamatsu
Photonics K.K.
8
IHI Corporation
4
Osaka Heavy Ion
Therapy Center
9
Sumitomo Heavy
Industries Ltd.
5
Varian Medical
Systems
10
▪ Here is the list of top 10 companies which
will be covered in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials (As per availability)
▪ If there are specific companies that you
would like to be included in the report, please
let us know via email
4.1 Key Company Profile
Illustrative

31
4.1.1 Hitachi Ltd.
▪ Hitachi Ltd. is involved in healthcare through its innovative technologies and
systems/solutions. They deliver digital technology and innovation for
implementing healthcare services tailored to individuals
▪ Hitachi's healthcare solutions include radiation therapy for improving the
quality of life in cancer treatment and in-vitro diagnosis
▪ A significant portion of its revenue generated from international markets,
particularly Asia, Europe, and North America
▪ Oct, 2023: Hitachi Asia Ltd. has announced the successful delivery of a
proton therapy system to the National Cancer Centre Singapore. This
marks Hitachi's inaugural proton therapy system to commence operations
in Southeast Asia
▪ May, 2022: Hitachi High-Tech Corporation, in a strategic move, has
initiated a partnership with Invivoscribe, Inc., a leading global provider of
blood cancer testing kits and services. The Partnership aims to accelerate
the molecular diagnostics and precision medicine businesses of both
companies
Hitachi Ltd. specializes in a wide
range of products and solutions,
including digital systems, power
and renewable energy solutions,
railway systems, and healthcare
products
Founded: 1910
Global HQ: Tokyo, JP
Revenue: $ 60.53 Bn
No. of Employees: 368,247
Locations: 150+
Website: hitachi.com
Recent Activity/ Press Coverage
$61.6 $60.9
$72.1
$0.9 $3.6
$4.7
32.6%
36.2%
31.4%
29.0%
30.0%
31.0%
32.0%
33.0%
34.0%
35.0%
36.0%
37.0%
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2020 2021 2022
Revenue ($ Bn) Net Income ($ Bn) Gross Profit margin
Key Financials

32
4.1.1 Hitachi Ltd. (continued)
Partnerships Ecosystem
Illustrative
GE Healthcare is a leading provider of medical imaging and information technology solutions
&partners with IBM Watson to offer AI-powered solutions for cancer diagnosis, and patient monitoring.
Philips Healthcare is a leading provider of healthcare technology solutions and partners with IBM
Watson to offer AI-powered solutions for patient engagement,and remote monitoring.
Siemens Healthineers is a leading provider of medical imaging and information technology solutions
and partners with IBM Watson to offer AI-powered solutions for cancer diagnosis, treatmentplanning,
and patient monitoring.
Cerner is a leading provider of electronic health records (EHR) and healthcare information
technology solutions.
Epic Systems is a leading provider of EHR and healthcare information technology solutions.
Major Distribution Partners

33
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.1.1 Hitachi Ltd. (continued)
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Illustrative

34
4.1.2 Company 2
Sources:
Founded:
Global HQ:
Revenue:
No. of Employees:
Locations:
Website:
Recent Activity/ Press Coverage
$93.5 $96.7
$104.8
$13.8 $19.1 $10.7
56.1%
53.2%
49.8%
46.0%
47.0%
48.0%
49.0%
50.0%
51.0%
52.0%
53.0%
54.0%
55.0%
56.0%
57.0%
0.0
20.0
40.0
60.0
80.0
100.0
120.0
2020 2021 2022
Revenue ($ Bn) Net Income ($ Bn) Gross Profit margin
Key Financials
Illustrative

35
4.1.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Illustrative

36
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.1.2 Company 2 (continued)
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Regulatory & Reimbursement Scenario

38
5.1 Regulatory Scenario
Illustrative
Illustrative
38
Pharmaceuticals and Medical Devices Agency (PMDA)
▪ The PMDA is a regulatory agency responsible for ensuring the safety, efficacy, and quality of pharmaceuticals and
medical devices in Japan
▪ It reviews and approves applications for marketing authorization, including those related to radiotherapy equipment,
ensuring compliance with Japanese regulatory standards
Ministry of Health, Labour and Welfare (MHLW)
▪ The MHLW oversees health-related policies in Japan and plays a crucial role in the regulation and supervision of medical
devices, including radiotherapy equipment
▪ It works in conjunction with the PMDA to establish and enforce regulatory standards, guidelines, and protocols for the
safe and effective use of radiotherapy technologies

39
5.2 Reimbursement Regulation
Illustrative
In Japan, the reimbursement and regulation of radiotherapy involve a combination
of public and private entities.
Public Insurance :
o Public reimbursement for healthcare services in Japan is primarily
managed through the national health insurance system, overseen by
the Ministry of Health, Labour and Welfare (MHLW).
o The government determines reimbursement rates within this universal
healthcare framework. The national health insurance system ensures
broad access to medical treatments, including radiotherapy, and the
MHLW plays a central role in establishing reimbursement policies and
rates
Private Insurance:
o Private reimbursement for healthcare services in Japan involves
collaboration between private insurance companies and healthcare
providers. Insurance companies negotiate and determine
reimbursement rates for services covered under private insurance
plans
o Private healthcare providers, such as hospitals and clinics, play a
crucial role
Government provide health insurance
coverage for more than 4 in 10
Population
Public
Insurance
38%
Employer-Sponsored
49%
Other Public
1%
Other Private
3% Uninsured
9%
Health Insurance Coverage, 2022
Illustrative
39

40
5.2 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Public and Private
 Public is a federal program that provides healthcare coverage to individuals who are
65 years of age or older, as well as certain younger people with disabilities
 Private is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

Life-sciences Market Research
Reports you can trust
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.

At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)

Click on the country to see the reports available
Global Coverage
North America
• US
• Canada
Latin America
• Brazil
• Argentina
• Mexico
• Ecuador
• Venezuela
• Senegal
Europe
• UK
• Germany
• France
• Italy
• Spain
• Russia
• Netherlands
• Sweden
• Romania
• Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
• UAE
• Saudi Arabia
• Turkey
• Lebanon
• Kuwait
• Qatar
Africa
• Egypt
• Kenya
• South Africa
• Algeria
• Nigeria
• Libya
• Tanzania
• Morocco

What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10

01 03
02 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process

Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation

2022
2023-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details
Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.

We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases

Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works

Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks

Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team

… and many more
Pi-SM
GmbH
Our Clients

I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say

Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID

Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.

Thank You
www.insights10.com
Email: insights@insights10.com
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

Japan Radiotherapy Market Analysis

Recommended

Recommended

More Related Content

Similar to Japan Radiotherapy Market Analysis

Similar to Japan Radiotherapy Market Analysis (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Japan Radiotherapy Market Analysis